Insights from 2023 ESMO Asia Annual Meeting


 

ESMO Asia 2023 Insights: "KEYNOTE-811 Study of Pembro + Trastuzumab & Chemo for HER2+ Metastatic Gastric/GEJ Adenocarcinoma"

142 views
January 17, 2024
Comments 0
Login to view comments. Click here to Login